相关临床试验
32
6 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
5
15.6%
已完成
15
46.9%
尚未招募
1
3.1%
招募中
7
21.9%
终止
4
12.5%
暂无批准数据
- A retrospective study of 49 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with inotuzumab ozogamicin achieved a 57.14% complete remission rate, with 71.4% of responders reaching minimal residual disease-negative status. - The study demonstrated reasonable efficacy even when patients received reduced doses due to financial constraints, with median doses of 1.72 mg/m²/cycle among responders versus 1.54 mg/m²/cycle among non-responders. - Hepatic sinusoidal obstruction syndrome occurred in 20.4% of patients overall, with 50% of transplant recipients developing this complication despite prophylactic measures. - One-year overall survival reached 51.7% for the entire cohort and 68.4% for patients who underwent subsequent transplant or CAR-T therapy.
- Real-world data from 877 patients and clinical trial data from 702 patients demonstrate that most cytokine release syndrome and neurological events with lisocabtagene maraleucel occur within 15 days of infusion and are not severe. - Among patients experiencing late-onset adverse events after day 15, the vast majority were grade 1/2 events that resolved without requiring intensive care unit-level management. - The findings support optimized monitoring strategies that could improve patient access to CAR-T therapy while maintaining safety standards across multiple blood cancer indications.
- Kite presented real-world data from 238 patients showing comparable safety and effectiveness outcomes for Yescarta CAR-T therapy administered in outpatient versus inpatient settings for relapsed/refractory large B-cell lymphoma. - The analysis found no significant differences in rates of cytokine release syndrome, neurologic events, or immune effector cell-associated neurotoxicity syndrome grade ≥3 between treatment settings. - Nearly 25% of outpatient-assigned patients avoided hospital admission within 30 days, and 50% avoided admission within 3 days, demonstrating potential cost-effective advantages. - The study supports expanding access to this potentially curative one-time treatment while reducing healthcare system burden and improving patient convenience.
- Leading experts at the 2025 Transplant and Cellular Therapy Meetings emphasize the critical need to address social vulnerabilities affecting patient access to stem cell transplants and CAR T-cell therapies. - Dr. Jeff Auletta, senior VP of health equity at National Marrow Donor Program, highlights significant scientific advancements in stem cell transplants and cellular therapies targeting infections and malignant diseases. - Healthcare leaders advocate for systemic changes to improve representation and access for vulnerable populations in advanced cellular therapies, emphasizing the moral responsibility of the medical community.
- Phase 2 ACCESS trial demonstrates 84% one-year overall survival rate using post-transplant cyclophosphamide for GVHD prevention in HLA-mismatched unrelated donor transplants. - Study shows improved GVHD-free, relapse-free survival rate of 48% compared to 38% in previous 15-UUMD trial, marking significant progress in transplant outcomes. - Results indicate successful outcomes regardless of number of HLA mismatches, potentially expanding treatment options for patients requiring stem cell transplantation.
- Dana-Farber researchers will showcase novel findings on multiple myeloma treatment outcomes based on Duffy genotype at the 2025 Tandem Meetings, revealing significant implications for personalized therapy selection. - Breakthrough research demonstrates how viral-antigen cross-reactivity influences gastrointestinal acute GvHD in stem cell transplants, potentially enabling better risk assessment and preventive strategies. - Dr. Joseph H. Antin receives prestigious Lifetime Achievement Award for pioneering contributions to stem cell transplantation, including groundbreaking work in GVHD pathophysiology and treatment.
- Omeros Corporation will present real-world data from 128 transplant patients treated with narsoplimab for TA-TMA under an expanded access program at the 2025 Tandem Meetings in Honolulu. - Key findings include outcomes from patients who received narsoplimab after failing eculizumab treatment, highlighting potential new treatment options for refractory cases. - The investigational antibody, which targets MASP-2, maintains critical immune functions while awaiting FDA approval, with breakthrough therapy and orphan drug designations already secured.
- Children from high-poverty neighborhoods face 25% transplant-related mortality compared to 20% in low-poverty areas, with Black children experiencing 65% higher risk of transplant-related mortality. - Insurance status significantly impacts survival rates, with Medicaid-insured children showing 48% five-year overall survival compared to 55% for privately insured patients. - Black children face severe disparities in donor matching, with only 19% finding suitable unrelated donors compared to 75% of White children, highlighting critical access barriers.
